Bio

Gerassimos Lascaratos is a Consultant Ophthalmic Surgeon specialising in glaucoma and cataract surgery at King’s College Hospital, London. He is a Reader in Ophthalmology, Faculty of Life Sciences & Medicine at King’s College London and is an internationally recognised expert in his field. 

Mr Lascaratos is a Fellow of the Royal College of Ophthalmologists (FRCOphth) and a member of the Royal College of Surgeons of Edinburgh (MRCSEd). He is also a member of the European Glaucoma Society (EGS) and the European Society of Cataract and Refractive Surgeons (ESCRS). He is the recipient of multiple national and international awards and is currently the co-Chief Investigator for a large multicentre randomised clinical trial on the role of nicotinamide to delay glaucoma progression (NAMinG trial) funded by a prestigious and highly competitive £2.0mil NIHR Efficacy and Mechanism Evaluation (EME) Programme grant.  

Mr Lascaratos prides himself on delivering the highest quality patient care with a focus on patient experience and clinical outcomes. He specialises in the medical, laser and surgical management of all types of adult glaucoma, including trabeculectomy and aqueous shunt devices, cutting edge minimally invasive glaucoma surgery, glaucoma revision surgery and complex cataract surgery, especially in patients with glaucoma. 

His cataract complication rate is less than 0.5 per cent, which is way below the national average, despite the complexity of the operations he performs. He also offers premium intraocular lenses, including toric lenses to correct astigmatism, and multifocal lenses to reduce spectacle dependence for near and distance. 

Mr Lascaratos completed the South Thames surgical training programme in ophthalmology in London and the highly sought-after subspecialty glaucoma fellowship programme at Moorfields Eye Hospital. He was the Clinical Lead for the ophthalmology urgent referral service at King’s College Hospital for several years and has extensive experience in Ophthalmology.

Based on his innovative PhD work in Glaucoma at University College London and his MSc by Research at St Peter’s College, University of Oxford he has international expertise in cellular bioenergetics in glaucoma and has served as the Principal Investigator at King’s College for multiple glaucoma clinical trials to investigate novel glaucoma treatments (intracameral SR bimatoprost, Rho-kinase inhibitors), evaluate emerging biomarkers for glaucoma and understand the molecular mechanisms influencing the outcome of glaucoma filtration surgery.